

Recent Papers That Will Help Or May Change Your Practice

Murray Rebner MD FACR FSBI

Professor of Diagnostic Radiology and Molecular Imaging
Director Division of Breast Imaging and Intervention

Murray Rebner

- I disclose the following financial relationships with relevant commercial interests:
- Previously- General Electric Medical Systems, Siemens Medical Systems, Hologic, Agfa- paid consultant.
- None currently

Goals And Objectives

- Review 5 recent papers which will impact practice
- Demonstrate how literature can affect use of different breast imaging modalities

Paper 1

- Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer
- Andrew Coldman et al
- JNCI J Natl Cancer Inst (2014) 106 (11): dju261 doi:10.1093/jnci/dju261

Paper 1

Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial

(Published 11 February 2014)

BMJ 2014;348:g366

Anthony B Miller, professor emeritus¹, Claus Wall, data manager¹, Cornelia J Baines, professor emerita¹, Ping Sun, statistician², Teresa To, senior scientist³, Steven A Narod, professor

Design

- **Interventions:** Women aged 40-49 in the mammography arm and all women aged 50-59 in both arms received annual physical breast examinations. Women aged 40-49 in the control arm received a single examination followed by usual care in the community.
 - **Main outcome measure:** Deaths from breast cancer.
-

Results

- The cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12).
- After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.

Conclusion

- Annual mammography in women 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available.
 - Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one overdiagnosed breast cancer for every 424 women who received mammography screening in the trial.
-

Study Design Problems

- Breast PE BEFORE randomization by nurses
- Quality of mammography poor-equipment and tech performance
- No tech/rad training
- Consulting radiologists resigned; physicist critical of mammography quality
- Surgeon decided if mammography detected lesions got biopsied



Garbage In; Garbage Out!

Paper 1

- Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer
- Andrew Coldman et al
- JNCI J Natl Cancer Inst (2014) 106 (11): dju261 doi:10.1093/jnci/dju261

Background

- Mammography screening randomized controlled trials show reduced breast cancer mortality in women 40 to 74 years.
 - Estimates from observational studies post screening implementation in different countries show varied findings.
 - Findings from seven Canadian breast screening programs analyzed.
-

Methods

- Study proposed by Canadian Breast Cancer Screening Initiative (CBCSI)
 - Supported by Public Health Agency of Canada (PHAC)
 - 12 breast cancer screening programs invited- 3 unable to provide data, 2 declined , 7 participated
-

Methods

- 7 provincial participants= BC, MN, ON, QC , NB, NS and NL.
- All programs used 2 view (mostly analog) mammography.
- Single radiologist interpretation.
- Entry based on self-referral; some received personal invitation letters and periodic reminder letters

Methods

- All programs had study approved by local IRB
 - All breast care managed by primary care physicians.
 - Reports received by primary care providers
 - Refer to tertiary centers when necessary.
-

Study Design

- Compare mortality of women who participated in screening with estimate of mortality if they did not
- Based estimate on experience of women in same area who were not screened.
- Separate cohorts created in each program- women with at least 1 screen between ages 40-79 and between 1990-2009. In cohort either until death or end of 2009.

Study Design

- Link between screening program database and provincial cancer registry
 - Established deaths from breast cancer from each cohort
 - Standardized mortality ratios calculated- observed mortality in participant group/province-specific expected mortality
 - Estimates of absolute benefit expressed as Numbers Needed to Participate (NNP) to prevent 1 breast cancer death within 10 years of entry
-

Results

- 2.79 million screened participants.
- 20.2 million life-person years of observation
- Maximum years post entry in provincial programs 12-20

Results

- Average breast cancer mortality 40% (95% CI=33-48%) lower than expected
 - Range of decreased mortality across provinces 27-59%
 - NNP(10): 40-49= 1247, 50-59=757, 60-69=552, 70-79=498
-

Discussion

- Results not influenced by trends in treatment or population awareness of breast cancer symptoms- contemporaneous cases in both populations
- Different results in different provinces due to age eligibility, annual screening for high risk population, annual screening of average risk groups etc.

Caveats

- Not an RCT!
 - Lower strength of evidence for population based service screening study
 - Multiple differences in methods between various provinces
 - Biases controlled as best as possible
 - HOWEVER, results still show reduction in breast cancer mortality and benefit from screening .
-

Benefit to You

- Results still show reduction in breast cancer mortality and benefit from screening .
- Use study to defend your screening guidelines

Paper 2

Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population

Bonafede, MM

ClinicoEconomics and Outcomes Research 2015:7 53–63

Background

- DBT benefits defined in multiple published papers
 - Increased cancer detection rate 15-30%
 - Decreased recall rate 15-40%
 - DBT now approved by FDA
 - CMS approved Medicare reimbursement January 1, 2015
-

Data

- Multicenter trials in Norway, Italy and USA
 - Oslo
 - STORM
 - US trial
-

Purpose

- Conduct DBT value analysis in US commercial health plans
 - Assess potential budget impact associated with DBT clinical benefits
-

Methods

- Economic model developed to estimate system-wide financial impact of annual DBT screening in hypothetical US managed care plan with one million members.
 - FFDM compared to FFDM +DBT to measure clinical and financial impact.
 - Value = difference between clinical and financial impact
-

Methods

- Major DBT economic value -reduce the number of recalled women for additional follow-up imaging and diagnostic testing services, and their costs.
- Other benefit- facilitate earlier diagnosis of cancers at less invasive stages when treatment costs are lower
- Offset additional reimbursement costs; produce net cost savings

Model Inputs: Methods

- Cancer detection rate identified via administrative claims
 - Defined as number of women with two breast cancer claims at least 30 days apart during the 6 months following the index screening event
 - Ancillary or laboratory claims alone were not sufficient to establish new cancer cases
-

Methods Scenarios

- For FFDM- breast cancer stage was distributed according to data from a study of 19,373 women with newly diagnosed stage (1-4) who received their primary cancer care at 8 National Comprehensive Cancer Network centers
-

Model Scenarios

- FFDM+DBT- model based on data from Skaane study
- Fixed percentage (18.3%) shift in stage-diagnosis (from stage 2-4 to stage 1) was estimated according to node negative/positive cancers detected in Oslo study
- 18.3% fewer stage 2-4 cancers were detected in the FFDM + DBT scenario, but compensated in the distribution by 21.9% more cancers diagnosed in stage 1.
- Stage 0 was assumed to remain constant based on reported trial results comparing FFDM with FFDM + DBT.²⁷

Model Scenarios

- FFDM+DBT- model based on data from Skaane study
- Fixed percentage (18.3%) shift in stage-diagnosis (from stage 2–4 to stage 1) was estimated according to node negative/ positive cancers detected in Oslo study
- 18.3% fewer stage 2–4 cancers were detected in the FFDM + DBT scenario, but compensated in the distribution by 21.9% more cancers diagnosed in stage 1.
- Stage 0 was assumed to remain constant based on reported trial results comparing FFDM with FFDM + DBT.²⁷

Post-diagnosis Cancer Treatment Costs

- Mean total health plan cost of newly diagnosed breast cancer patient in year following diagnosis derived from administrative claims data.
- Value was distributed across stages 1–4 using same stage distribution of breast cancer costs as presented in study of costs for women with newly-diagnosed breast cancer by disease stage, and matched to non-cancer controls.

Costs

- Stage 1 costs 25.7% less than mean overall cost
 - Costs for stages 2, 3, and 4= 13.4%, 77.1%, and 281.4% higher than mean overall cost.
-

Cost

- Cost distribution by stage 1-4 calculated using estimates from the claims database analyses.
 - Stage 0 costs estimated using percentage difference between stage 0 and stage 1 costs derived from 4-year longitudinal study in a US HMO.
 - The difference (stage 0 18.5% <stage 1) applied to stage 1 estimate above to yield stage 0 cost.
-

Results

- 1,521,667 women (mean age 50.7 years) met study inclusion criteria (evaluate follow-up service utilization and costs).
- Age distribution:
 - age 40–49 years= 40.9%
 - age 50–59 years= 39.8%
 - age 60–69 years= 17.6%
 - age 70–75 years= 1.6%

Results

- From claims database costs of follow-up services in the 6 months following abnormal or inconclusive mammogram estimated at \$1,200
 - Prevalence rate= 4.65 per 1,000, comparable to other studies
 - Mean costs- newly diagnosed breast cancer patients were \$58,615 in the year following diagnosis
-

Results

- 84,549 women aged 40–75 years from one million member health plan
- Annual screening mammography
- Assume 100% compliance for each group

Results

- Assumption- current recall rate=15.35%
- Assumption- FFDM + DBT decrease rate to 10%
- 4,523 women screened with FFDM + DBT avoid use of follow-up services
- Total annual cost savings to the health plan- \$2.4 million

Results

- \$5.5 million savings from avoiding follow-up services
- \$1.2 million from earlier detection of breast cancer
- Incremental cost of \$4.2 million by adding DBT to screening.
- $\$5.5\text{M} + \$1.2\text{M} = \$6.5\text{M} - \$4.2\text{M} = \$2.5\text{M}$ net savings

Impact

- DBT clinical benefit shown
- Challenge remains for reimbursement
- Medicare payments (+\$57) obtained
- Few private carriers pay
- Presentations required financial plus clinical data
- More financial data needed
- This paper good start!

Paper 3

- Abbreviated Breast Magnetic Resonance Imaging(MRI): First Post-contrast Subtracted Images and Maximum-Intensity Projection—A Novel Approach to Breast Cancer Screening With MRI
- *Christiane K. Kuhl, et al.*
- *J Clin Oncol 32:2304-2310*

Introduction

- Breast MRI has high sensitivity for breast cancer.
 - MRI- second-line imaging method for patients with equivocal findings on mammography or ultrasound.
 - Use for pre-op staging of breast cancer controversial
 - Find unknown breast primary and R/O silicone implant rupture
-

Screening

- Breast MRI screening increased over the past decade.
- For high risk population MR downstages breast cancers and reduces interval cancers.
- Indirect evidence (no RCT's) suggests MRI screening helps improve the prognosis of population at elevated risk.

Screening MRI Problems

- Lack of sites offer high-level breast MRI; limits clinical access to screening MRI
 - Breast MRI screening has high direct and indirect costs.
 - Current breast MRI protocols time consuming to acquire and read.
 - Magnet time up to 40 minutes; several hundred-thousands of images.
-

Mammography

- Mammographic screening highly standardized relatively simple procedure.
- Clinical examinations infrequent
- Studies interpreted by radiologists who batch read up to 100 mammograms per hour.

New Concept

- Breast MRI to mimic screening mammography.
 - Abbreviated MRI protocol:
 - Early post-contrast sequence
 - Standard image reconstruction (MIP) allows fast overview of the imaging volume
 - Expert radiologists interpret protocol.
 - Numerous pulse-sequence protocols used and most mimic
-

Goal

- Reduce image acquisition time
- Reduce reading time
- Increase access to screening breast MRI.

Methods

- Prospective IRB-approved reader study
- Conducted over 18 months (January 2009 to June 2010), followed by 2-year validation period.
- Primary objective to investigate whether abbreviated MRI protocol sufficient to identify breast cancer in a screening cohort.

Methods

- Secondary objective- compare diagnostic accuracy and cancer yield of abbreviated protocol(AP) with those of regular diagnostic breast MRI protocols in same individuals.
- Predicted AP would be associated with reduced diagnostic accuracy.
- Acceptable to lose some sensitivity of regular screening breast MRI in exchange for acquisition and interpretation speed.

Inclusion Criteria

- Consecutive women referred for screening breast MRI on clinical history.
- Degree of familial risk categorized as mild, moderate, or high based on BRCAPRO
- Included personal history of breast cancer but only assessed contralateral breast in analysis

Methods

- Women imaged between days 6 and 12 of menstrual cycle.
- Normal clinical examination on MRI day
- Normal or benign digital mammogram
- Negative or benign ultrasound study needed for women with heterogeneously or extremely dense breasts

Pulse Sequences

- Pre-contrast axial T1-weighted gradient echo images
 - Post-contrast axial T1-weighted gradient echo images
 - Sequence 1 images subtracted from sequence 2 images to yield first post-contrast subtracted (FAST) images
 - Fast images fused to yield MIP sequence
-

Methods

- FDP = AP, plus the non-subtracted and subtracted images of the remaining four post-contrast phases of the dynamic series and additional coronal T1-weighted and axial T2-weighted pulse sequences.
- Bilateral two-view full-field digital mammography (plus additional views and spot magnification views where appropriate) performed and double read.
- Systematic whole-breast screening ultrasound performed using dedicated equipment

Reader Study

- Prospective image interpretation after each MRI examination.
- Two experienced readers (18 and 6 years experience, annual MR caseloads 800/year)
- Blinded to clinical histories
- AP images read 1st (MIP 1st) then FDP

Results

- 443 initial screens; 163 had two annual screening rounds = 606 breast MRI studies
- Mean and median age = 54.2 and 52.6 years, one third premenopausal; two thirds postmenopausal.
- All patients had digital mammography
- High-frequency ultrasound, with negative or benign results performed in 427 of 606 screening rounds

Results

- ***MRI Acquisition Time:***
 - AP 3 minutes.
 - FDP 17 minutes.
 - ***Time to Read:***
 - MIP 2.8 seconds
 - AP 28 seconds.
 - Time to read the FDP not measured.
-

Results

- Eleven breast cancers diagnosed in the 606 annual screening round (4 DCIS; 7 invasive carcinomas)
- Additional cancer yield of 18.15 per 1,000 screening rounds
- Breast cancer incidence of 11 of 443 (25 per 1000)
- All invasive cancers small T1 N0; median size 8 mm.
- Distribution of nuclear grading of invasive cancers as well and DCIS skewed toward high-grade lesions
- No interval cancers

Results

- No difference in sensitivity (91%) between AP and FDP
- NPV 99.8% for MIP and 100.0% for complete AP and FDP readings
- No difference between specificity and PPV for AP reads vs. FDP (94.3% v 93.9% and 24.4% v 23.4%, respectively).

Implications and Questions

- FAST MRI proof of concept demonstrated
- No decrease in diagnostic performance
- Reimbursement and utility challenged
- Shorter scanning and interpretation times = decreased cost/study but offset by increased volumes
- Applicable to US rads who read less?
- Change in ACR BMRAP?
- ACRIN study planned

Paper 4

- Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The Somolnsight Study
 - Brem RF et al.
 - Radiology 2014: DOI: <http://dx.doi.org/10.1148/radiol.14132832>
-

Background

- Mammography sensitivity as high as 85%, but as low as 48% in women with extremely dense breasts.
- Breast density independent risk factor- estimates of relative lifetime risk 2.8 to 6.0
- Risk increases in proportion to percentage breast density
- >1/2 women under 50 and 1/3 women 50 or older with breasts >50% dense.
- Around 28%–30% of breast cancers associated with breast density vs. approximately 5%–10% due to *BRCA1* or *BRCA2* gene.

Background

- Supplementary breast cancer screening indicated for segments of population
 - MRI proven benefit for high risk population
 - US screening for high risk patients unable to undergo MRI screening
 - US screening for normal risk population with dense breasts?
-

Background

- Handheld screening breast US increases detection of small, node-negative breast cancers in women with dense breasts.
- Most studies focused on high-risk women with additional risk factors for breast cancer.
- Reliability of handheld US for screening controversial- false-positive rate, variability between operators, considerable physician time required for acquisition.

Background

- 3D automated breast sonography (ABS) possible solution for intermediate-risk women with dense breasts.
- With ABS each breast imaged in sections with automated 15.4-cm 14–6-MHz linear-array transducer.
- Images reconstructed coronally and viewed at dedicated workstation
- Average interpretation time =2.9 minutes.
- Purpose of study to determine improvement in breast cancer detection
- ABS+ screening mammography vs. screening mammography alone is asymptomatic women with dense breasts.

Methods

- All sites one ABS device (somo.v U-systems)
- Multi- institutional IRB- approved study from 2009 to 2011.
- Included asymptomatic women 25 years and older with heterogeneously (50%–75% dense) or extremely (> 75% dense) dense breast parenchyma .
- Women with a history of lumpectomy, contralateral mastectomy, breast augmentation, or implants were included.

Imaging

- Standard digital CC/ MLO views per screening protocol
- Trained tech performed ABS US study
- Each breast imaged in three views with automated 15.4-cm 14–6-MHz linear-array transducer,
- Up to 1000 2D images acquired in transverse plane; breast imaged in three parts: the central (AP), lateral, and medial portions
- Additional obtained as necessary to cover entire breast.
- Standardized review process uses coronal plane for quick navigation through the breast, plus “survey mode,” (similar to cine and allows rapid review of many images).
- Acquisition time for each view approximately 60 seconds; total examination time about 15 minutes.
- Images reconstructed in coronal plane and were 3D for radiologist interpretation

Interpretation

- Screening mammograms- interpreted prospectively by one of 39 radiologists at 11 clinical sites. (BI-RADS 0,1,2). BI-RADS category 3 rating assigned in small number of patients (19 patients, 0.1%). None had cancer.
- Breast density assessed by radiologist and BI-RADS classified : type 1 (“almost entirely fat”), type 2 (“scattered fibroglandular densities”), type 3 (“heterogeneously dense”), or type 4 (“extremely dense”).

Interpretation

- Screening mammographic images reviewed first without ABS
- BI-RADS risk assessment assigned, recorded and locked
- same investigator interpreted the ABS images with screening images.
- BI-RADS risk assessment category assigned to ABS images; final combined impression (mammo + ABS) recorded
- Routine management (BI-RADS 1 and 2) or immediate management (BI-RADS 0,3,4,5) recommended
- BI-RADS 0,3,4,5= recall

Interpretation

- To minimize inter-observer variation:
- Radiologists Mammography Quality Standards Act certified.
- All radiologists participated in standardized training program (Web-based training, Web-based one-on-one training, and on-site training with radiologist experienced in ABS) prior to study initiation.

Follow-up

- immediate management= recommendation from either individual mammographic assessment or combined assessment.
- Women with normal, benign, or probably benign findings followed up for 12 months (88% compliance)
- Only cancers detected as a result of original screening, (screening mammography or ABS) were considered screening-detected cancers. (Interval cancers not included)

Results

- 2301 recalls- 1957 from combined read, 344 from screening mammography alone.
 - 13,107 had negative mammogram; 2407 (18%) recalled from combined read
 - From recalls 112 breast cancers identified:
 - 82 identified by mammography
 - 30 cancers identified with ABS alone (21%).
-

Cancer Results

- ABS-only detected cancers more likely to be invasive vs. mammo-only detected (28 of 30, 93.3%) versus 62.2% (51 of 82), with $P = .001$.
- Larger percentage of invasive low-stage cancers (IA, IB) were detected with ABS alone compared with screening mammography (20 of 30, 66.7%) versus 45.1% (37 of 82).

Supplementary Cancer Detection Yield

- Mammography and ABS- yield of 7.3 cancers per 1000 women screened
 - Mammography alone- 5.4 cancers per 1000 women screened
 - Difference in yield- 1.9 detected cancers per 1000 women screened
 - Mammography alone- increase in recall rate- 150.2 per 1000 women screened
 - Combined approach- 284.9 per 1000 screened
-

Results


- 26.7% sensitivity increase for combined approach vs. mammography alone
- 13.4% decreased specificity for combined approach vs. mammography alone.
- For combined approach- increase in biopsy rate 36.0 per 1000 women screened
- PPV1 decreased more with combined approach- 3.6% versus 2.6% mammography alone
- PPV3 decreased more with combined approach- 14.0% versus 9.8% for mammography alone

Conclusion

- MRI limited by high cost, relative lack of availability, variable patient tolerance, and the requirement for contrast material injection
- US inexpensive, well tolerated and no ionizing radiation.
- Increase cancer detection with supplementary ABS= 1.9 cancers per 1000 women screened,

D.E.N.S.E.® State Efforts

Click on your state to find information about "mandatory breast density notification" legislative efforts.



PINK: Enacted Law — RED: Introduced Bill — BLUE: Working on Bill — WHITE: No Action — BLACK ★ : Insurance Coverage Law

Implications

- 20 states (as of February 2015) with breast density legislation
- Only 4 states mandate insurance coverage for screening breast US in women with dense breasts
- Federal breast density bill introduced (February 2015); no mandated insurance coverage
- More pressure to do breast US? (women and competitors)
- FAST MRI alternative?

Paper 5

- Factors Associated with Repetitive Strain, and Strategies to Reduce Injury Among Breast-Imaging Radiologists
-
- Thompson AC, Kremer Prill MJ, Biswal S et. al.
- J AM Coll Radiol. 2014 Nov;11(11):1074-9

Purpose

- To investigate prevalence of repetitive strain injury (RSI) in breast imagers
 - Examine factors associated with RSI
 - Determine strategies to reduce injuries
-

Methods

- Survey to 2618 SBI physician members in 2012
 - 727(28%) response
 - Pain levels before and after digital imaging measured
 - Association between RSI and work trends analyzed
-

Methods

- Survey based on “Ergonomic Survey” instrument
- Dept. position, digital vs. analog use, hours/day at PACS workstation
- Hours/day in awkward position, current RSI and prior Dx of repetitive strain syndrome(RSS)

Additional Information

- Age information grouped 5 year intervals <30->65
 - Pain sites/discomfort relating to work tasks
 - Use of ergonomic devices at work- mouse/peripheral input device, adjustable chair, adjustable table
-

Methods

- Univariate and multivariate LR done.
 - Assess association between RSI symptoms and:
 - Ergonomic score index, desire for ergonomic training, age, number of hours in awkward position or number of hours at computer/PACS workstation.
-

Results

- 584/727 (80%) used breast imaging RWS/PACS
 - 18% with ergonomic mouse/PID
 - 56% with adjustable tables
 - 92% with adjustable chairs
 - 87% no ergonomic training; 85% wanted it
-

Results

- 60% with RSI
 - 33.3% RSI's treated
 - Most common sites- neck>wrists>elbows
-

Results

- Odds of current RSI symptoms correlated with:
- Decreasing age ($p=.0004$)
- More hours working/day ($p=.0006$)
- More hours in awkward position (bent wrist , stooping) ($p<.0001$)

Results

- Increased pain after switch to PACS ($p < .001$)
 - If used ergonomic training/ergonomic mouse/chair/table then decreased pain ($p < .001$)
 - Of 438 rads who used ergonomics, 392 continued with 1/more devices
 - For 1 ergonomic device used, 38% less likely to report RSI symptoms
 - 630 no prior training; if had current symptoms or prior Dx/Rx for RSS more likely to want training vs. those without prior symptoms/injury
-

Discussion

- Other studies (all radiologists) with similar results- Boiselle PM, J Am Coll Radiol 2008;5:919-23.
- 80% in Boiselle study improved RSS Sx after ergonomic training
- Similar location of injuries with breast imagers vs. all radiologists
- Increased RSI prevalence in younger breast imagers- working more hours? Change in age distribution over time?

Summary

- Prevalence of current RSI symptoms =(60.2%); RSS= (33.3%).
 - 80% used RWS; 18% used ergonomic mouse/peripheral input device, 56% used adjustable tables, 92% used adjustable chairs
 - 13% participated in ergonomic training
 - 85% non-participants interested in ergonomic training if available.
-

Summary

- Statistically significant trend for odds of current RSI symptoms to increase with: decreasing age, greater number of hours spent working each day and greater number of hours spent in awkward positions (wrist bent, stooping)
-

Summary

- Increase in pain level after implementation of PACS workstation,
- Decrease in pain level after ergonomic training, use of ergonomic mouse, PID adjustable chair, or adjustable table.

Summary

- Improved ergonomics may help prevent RSIs
- Advise radiology departments take aggressive action to prevent radiologist injury through work-based ergonomic training and ergonomic changes in the reading room.